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Abstract  26 
Evaluation of the epitope specificities, location (systemic, mucosal) and effector function of 27 
antibodies elicited by novel HIV-1 immunogens engineered to improve exposure of specific 28 
epitopes is critical for HIV-1 vaccine development. Utilizing an array of humoral assays, we 29 
evaluated the magnitude, epitope specificity, avidity and function of systemic and mucosal 30 
immune responses elicited by a vaccine regimen containing Env cross-linked to a CD4 mimetic 31 
miniprotein (gp140-M64U1) in rhesus macaques. Crosslinking of gp140 Env with M64U1 32 
resulted in an earlier increase in both the magnitude and avidity of the IgG binding response 33 
compared to Env protein alone. Notably, binding IgG responses at an early time point correlated 34 
with Antibody Dependent Cellular Cytotoxicity (ADCC) function at the peak immunity time point, 35 
which was higher for the crosslinked Env group compared to the Env group alone. In addition, 36 
the crosslinked Env group developed higher IgG responses against a linear epitope in the C1 37 
gp120 region of the HIV-1 envelope glycoprotein. These data demonstrate that structural 38 
modification of the HIV-1 envelope immunogen by crosslinking gp140 with the CD4 mimetic 39 
M64U1 elicited an earlier increase of binding antibody responses and altered the specificity of 40 
the IgG responses that correlated with the rise of subsequent antibody-mediated antiviral 41 
functions.    42 
 43 
Importance 44 
The development of an efficacious HIV-1 vaccine remains a global priority to prevent new cases 45 
of HIV-1 infection. Of the six HIV-1 efficacy trials to date, only one has demonstrated partial 46 
efficacy, and the immune correlates analysis of this trial revealed a role for binding antibodies 47 
and antibody Fc mediated effector functions. New HIV-1 envelope immunogens are being 48 
engineered to selectively expose the most vulnerable and conserved sites on the HIV-1 49 
envelope with the goal of eliciting antiviral antibodies. Evaluation of the humoral responses 50 
elicited by these novel immunogen designs in nonhuman primates is critical for understanding 51 
how to improve upon immunogen design to inform further testing in human clinical trials. Our 52 
results demonstrate that Env structural modifications that aim to mimic the CD4 bound 53 
conformation can result in earlier antibody elicitation, altered epitope specificity and increased 54 
antiviral function post immunization.  55 
 56 
Introduction 57 
A critical component in the path toward the development of a successful HIV-1 vaccine 58 
strategy is definition of the epitope specificities, location (systemic, mucosal) and effector 59 
function of antibodies elicited by novel HIV-1 immunogens engineered to improve exposure of 60 
specific epitopes. There is a growing body of evidence from animal models that antibodies can 61 
control virus replication (1-4) through elimination of infected cells (4), engagement of Fc-62 
mediated antibody effector functions to limit founder viruses (2), and delay acquisition and/or 63 
prevent the establishment of infection (5-15) through mechanisms including virus neutralization 64 
(8-14, 16) and antibody Fc-mediated anti-viral functions (11, 15, 17). Together, these studies 65 
include both passive immunization strategies and vaccine approaches that have tested a range 66 
of antibody specificities, antibody isotypes and effector functions (broadly neutralizing, non-67 
broadly neutralizing and antibody Fc-mediated antiviral activities), thus demonstrating that there 68 
is much diversity in the types of antibodies that may protect. However, there remains a gap in 69 
understanding how different immunogen designs specifically impact antibody specificities, 70 
kinetics and antiviral functions (i.e. neutralizing and non-broadly neutralizing). 71 
 72 
 There are numerous challenges for inducing broadly neutralizing antibody functions by 73 
vaccination, including but not limited to shielding of key epitopes by glycans, difficulty in 74 
presentation of the correct Env structures, and the unusual traits of broadly neutralizing 75 
antibodies (18, 19). In contrast, the one partially efficacious HIV-1 vaccine in humans 76 
demonstrated a potential role for non-broadly neutralizing antibodies in preventing HIV-1 77 
acquisition (20). Non-broadly neutralizing antibodies include CD4-induced (CD4i) antibodies that 78 
target epitopes whose exposure is triggered by binding of HIV-1 Env gp120 to CD4 on the host 79 
cell. A recent study demonstrated that CD4i antibodies correlated with viremia control following 80 
mucosal challenge in rhesus macaques (3).    81 
  82 
 HIV vaccine strategies can involve modifying the structure of Env for improved exposure 83 
of CD4i epitopes. CD4i epitopes include co-receptor binding sites (21, 22) that are highly 84 
conserved (23-25) as well as variable loop domains (26, 27), some of which are easily elicited 85 
during natural HIV-1 infection (24, 28, 29). One immunogen design approach has utilized co-86 
expression of CD4 in a single molecular structure with HIV-1 Env to promote binding and 87 
complex formation of CD4 and Env (3, 30-34). Another approach involves small molecule CD4 88 
mimetic compounds, which have been shown to inhibit HIV-1 virus entry by competitively 89 
binding to CD4 binding site (CD4bs) (35, 36). A recent study further showed that CD4 mimetic 90 
compounds can activate or inactivate primary HIV Env trimers depending on properties of the 91 
CD4 mimetics and the Env trimer, and how many subunits of the trimer are bound (37). Several 92 
studies have explored biochemical cross-linking of synthetic CD4 mimetic molecules with Env 93 
proteins for improved CD4i epitope exposure (31, 38-41). In particular, a CD4-mimetic 94 
miniprotein M64U1, has been shown to expose both CD4i epitopes and co-receptor binding 95 
sites when covalently conjugated to Env gp140 (38), eliciting increased titers of CD4i antibody-96 
mediated neutralization in rabbit immunization studies (38, 42). The gp140-M64U1 cross-linked 97 
vaccine was further tested in macaques (Bogers et al, submitted) and was shown to alter the 98 
kinetics of B cell responses and levels of neutralization and ADCC responses. Here we further 99 
characterized the magnitude, specificity, and kinetics of binding antibody responses and 100 
examined the correlation between these parameters of binding antibody response with that of 101 
antibody functions, providing novel evidence that the cross-linked gp140-M64U1 complex can 102 
impact both the binding properties of and the antiviral functions mediated by Env-specific 103 
antibodies in primates.   104 
 105 
MATERIALS AND METHODS 106 
Animal study design.  107 
Rhesus macaques of Chinese origin were housed at the Biomedical Primate Research Center 108 
(BPRC), The Netherlands. The study protocol and experimental procedures were approved by 109 
the institute’s animal ethical care and use committee and were performed in accordance with 110 
Dutch law and International ethical and scientific standards and guidelines (Bogers et al, 111 
submitted).  The study consisted of four groups of 6 animals each (Table 1).  One group (gp140 112 
group) received intramuscular immunization with 100 mg gp140 protein with the variable loop 2 113 
(V2) deleted (SF162∆V2 gp140), administered in adjuvant MF59; the second group (gp140-114 
M64U1 group) received immunizations with 100 mg gp140 cross-linked with the CD4-mimetic 115 
M64U1 (gp140-M64U1, produced by incubating gp140 with M64U1-SH that contains an 116 
additional sulfhydryl group on the side chain of Lys4 at 1:3 gp140:M64U1-SH ratio) (38, 42), 117 
also in MF59. In addition, two control groups received either the M64U1/MF59 only (50 mg) or 118 
mock immunizations. All protein immunizations were delivered intramuscularly at week 0, 4, 24, 119 
36, and 107 of study.    120 
Binding antibody multiplex assay (BAMA).  121 
Env-specific IgG and IgA responses in serum and in mucosal samples were measured as 122 
previously described (29, 43, 44). For quantification of IgA responses, IgG was depleted from 123 
sera using Protein G HP MultiTrap Filter Plates (GE Healthcare Life Sciences).  Mucosal 124 
specimens were filtered, buffer-exchanged, and concentrated to equal volumes before 125 
measurement of total and specific antibody. The rectal wash samples were examined and none 126 
had visual blood contamination. Total IgG concentration in each mucosal sample was 127 
determined by macaque total IgG ELISA, and specific activity was calculated as: Specific 128 
activity= (MFI x dilution)/total antibody. For characterization of CD4 binding site (CD4bs) and 129 
CD4-inducible (CD4i) antibodies, a CD4bs and CD4i differential binding antigen panel was used 130 
for BAMA, which includes the wildtype (WT) YU2 gp120 core, resurfaced stabilized core 3 131 
(RSC3), HXB2 8b core, and their mutants containing mutations to amino acids that are known to 132 
be required for binding by CD4bs or CD4i antibodies (proteins kindly provided by Dr. Mascola, 133 
Vaccine Research Center). Relative levels of CD4bs and CD4i specificities were calculated as 134 
the MFI of WT: MFI of mutant ratios for samples that bound to both WT and mutant with 135 
MFI>100 and at least 3-fold over the MFI of matched baseline (wk0) samples.  136 
Linear epitope mapping peptide microarray. Linear epitope mapping was performed as 137 
previously described (45, 46) with modifications. Briefly, array slides were provided by JPT 138 
Peptide Technologies GmbH (Berlin, Germany) by printing a peptide library designed by Dr. B. 139 
Korber (Los Alamos National Laboratory) onto Epoxy glass slides (PolyAn GmbH, Germany). 140 
The library contains overlapping peptides (15-mers overlapping by 12) covering 7 full-length 141 
HIV-1 gp160 Env consensus sequences (Clades A, B, C, D, Group M, CRF1 and CRF2)(46). 142 
Sequences of peptides contained in the peptide library have been previously published (47).  143 
Three identical subarrays, each containing the full peptide library, are printed on each slide. All 144 
serum samples were diluted 1:250 and hybridized to the slides using a Tecan HS4000 145 
Hybridization Workstation, followed by incubation with DyLight 649-conjugated goat anti-rabbit 146 
IgG (Jackson ImmunoResearch, PA). Fluorescence intensity was measured using a GenePix 147 
4300 scanner (Molecular Devices) and analyzed with GenePix software.  Binding intensity of the 148 
post-immunization serum to each peptide was corrected with its own background value, which 149 
was defined as the median signal intensity of the prebleed serum for that peptide plus 3 times 150 
the standard error among the 3 subarrays on slide.  151 
Surface Plasmon Resonance (SPR) test for binding avidity. SPR tests were performed as 152 
previously described on BIAcore 4000 instruments (20, 48). Binding dissociation rate constant 153 
(kd) and binding magnitude (response unit, RU) were measured for IgG purified from NHP sera, 154 
at 200 µg/ml, against a panel of HIV-1 Env glycoproteins including ConS gp140, SF162∆V2 155 
gp140, MN gp120, and gp41 MN. Env proteins were immobilized as previously described, and 156 
avidity score was calculated as RU/kd (20).   157 
Neutralization assays. Virus neutralization assays were performed on TZM-bl cell line, using 158 
replication competent or pseudotyped viruses grown in human peripheral blood mononuclear 159 
cells (PBMC) as previously described (49). Serial dilutions of serum samples were tested for 160 
neutralization of a panel of Tier 1 (SHIV-SF162P4 and SHIV-1157iEL-p, both as replication 161 
competent viruses) and Tier 2 (SHIV-SF162P3.5 and SHIV-89.6P.18, as pseudotyped viruses, 162 
and SHIV-89.6 and SHIV-1157ipd3N4, as replication competent viruses) SHIV viruses in TZM-163 
bl cells.  164 
ADCC assays. ADCC assays were performed as previously described by Pollara et al. (50), 165 
using CEM.NKRCCR5 cells coated with recombinant HIV-1 SF162gp120 as target cells, and 166 
PBMC obtained from an HIV-seronegative donor as effector cells. The ADCC-mediating 167 
antibody titer was defined as the reciprocal of the highest dilution indicating a positive GzB 168 
response (>8% GzB activity) after background subtraction as previously described (50).  169 
 170 
Statistical analysis. Differences in the levels of antibody responses between the 2 vaccine 171 
groups or between vaccine and control groups were tested using the Wilcoxon rank sum exact 172 
test with false discovery rate (FDR) controlled using the Benjamini–Hochberg method (51), 173 
performed with SAS. Correlations between binding antibody responses (binding magnitude from 174 
BAMA and epitope mapping assays and dissociation rate from SPR assays) and antibody 175 
functions (ADCC and neutralization assay) were tested using the Spearman correlation test with 176 
FDR controlled using the Benjamini-Hochberg method.   177 
RESULTS 178 
Rhesus macaques were immunized with SF162∆V2 gp140 protein 5 times, either alone (gp140 179 
group, 6 animals) or cross-linked with a CD4 mimetic miniprotein (gp140-M64U1 group, 6 180 
animals) (Bogers et al, submitted). Env-specific antibody responses, including systemic and 181 
mucosal binding specificities and antibody avidity, were evaluated with samples collected at wk 182 
6 (2 weeks post 2nd immunization), wk 26 (2 weeks post 3rd immunization), wk38 (2 weeks post 183 
4th immunization), and wk107 (time of 5th immunization that is 71 weeks after 4th immunization).  184 
Early Env-binding IgG response with gp140-M64U1 vaccine.   185 
To characterize the development of Env-specific binding antibody responses over time, we 186 
tested longitudinal serum samples of the vaccinated animals for their binding to 187 
SF162gp140ΔV2 (the immunogen), ConS gp140 (Group M consensus (52-54), MN gp120, and 188 
MN gp41 proteins in binding antibody multiplex assays (BAMA). Among these 4 Env antigens 189 
tested, the highest response was seen in binding to SF162gp140ΔV2 (the vaccine strain), 190 
followed by ConS gp140. Similar kinetics were observed for the development of the Env-specific 191 
IgG responses against the 4 Env antigens examined. Serum IgG specific for the Env proteins 192 
were detectable as early as wk 6 (2 weeks after the 2nd immunization) for all 4 Env antigens 193 
tested in both the gp140 and gp140-M64U1 groups (Fig 1A-1D). The responses generally 194 
peaked at wk 26 (2 weeks after the 3rd immunization), with wk 38 (2 weeks after the 4th 195 
immunization) levels comparable to that of wk 26 for both groups. The responses measured at 196 
wk 107 (71 weeks after the 4th immunization) declined as expected, followed by a boost in the 197 
responses measured at wk 113 (6 weeks after the 5th immunization) (Fig 1A-1D).   198 
While the peak levels of binding antibody responses (wk 26 and wk 38) were generally 199 
comparable between the two groups, the gp140-M64U1 group showed significantly higher 200 
binding antibody responses at wk 6, revealing faster kinetics in the development of the anti-Env 201 
responses. For all 4 Env proteins tested, binding by the wk 6 sera was much higher for the 202 
gp140-M64U1 group compared to the gp140 group, with a FDR_p value (Wilcoxon rank sum 203 
exact test p value controlled for false discovery rate (FDR) with the Benjamini-Hochberg 204 
method) of 0.014  (Fig. 1A-1D, Table 2). Binding responses to all 4 Env proteins were again 205 
comparable between the gp140 and the gp140-M64U1 groups after the last immunization at wk 206 
113 (Fig. 1A, Table 2).   207 
Decreased Linear C1 Epitope IgG with gp140-M64U1 vaccine.   208 
Wk26 (2 weeks post 2nd immunization, the peak immunity time point) serum samples from all 209 
immunized animals were profiled for binding antibodies against gp160 linear epitopes using 210 
peptide microarray.  The HIV-1 Env peptide library contains overlapping peptides covering 7 full-211 
length consensus gp160 sequences (clade A, B, C, D, group M, CRF01 and CRF02). Serum 212 
IgG from both the gp140 and gp140-M64U1 groups bound epitopes in the C1, C2, V3, C4, V5 213 
and C5 regions of gp120 (Fig. 2A, 2B, and 2C) and the gp41 immunodominant (ID) region of 214 
gp41 (Fig. 2A, 2D and 2E). The magnitude of binding to these epitopes was generally 215 
comparable between the 2 immunized groups at wk 26 (Fig. 2A), with the exception of epitope 216 
C1.2-binding, which was significantly higher for the gp140 group compared to the gp140-M64U1 217 
group (FDR_p = 0.038; Fig. 2B and 2C, Table 2). Interestingly, this C1.2 linear epitope was 218 
identified in epitope mapping studies of the RV144 Thai trial, and plasma IgA binding to the 219 
corresponding C1 peptide covering the entire epitope region (C1_104. AE: 220 
MQEDVISLWDQSLKPCVKLTPLCV) correlated with increased risk of HIV-1 infection (i.e. 221 
decreased vaccine efficacy) in the secondary/exploratory immune correlate analysis of the trial 222 
(20). To further evaluate the kinetics and magnitude of this response, we measured the level of 223 
serum IgG response to linear C1_104.AE peptide over time by BAMA. Binding response against 224 
C1_104.AE was significantly higher for the gp140 group than the gp140-M64U1 group at wk26 225 
(FDR_p=0.014; Fig. 2F, Table 2), which is consistent with the trend observed in wk26 linear 226 
epitope mapping data (Fig. 2 A, B, and C). Similar to binding responses against Env proteins, 227 
binding responses to C1_104.AE peaked at wk 26 and wk 38, declined at wk107, and then 228 
increased again at wk113, after the fifth immunization. 229 
We modeled this C1_104 epitope in the monomeric subunit of gp120 from the SOSIP Env trimer 230 
structure(55), which is representative of the pre-fusion conformation, and found that it is 231 
exposed on the monomeric gp120 surface (Fig. 2G, red ribbon).  In the CD4-bound state, the 232 
formation of the bridging sheet results in the C-terminal half of the C1_104 epitope bending ~90 233 
degrees relative to the epitope in the SOSIP structure (Fig. 2G, pink ribbon). This bending 234 
results in a >30Å displacement in the position of the C-terminal residue of the C1_104 epitope, 235 
which in turn contacts CD4(56).  Given the large conformational change and associated burial of 236 
C-terminal residues upon contacting CD4, antibodies that recognize C1_104 in the unbound 237 
conformation therefore may not be able to recognize the epitope in the CD4 bound state.  While 238 
the effect of CD4 binding on the conformation of the C1_104 epitope in a V2 deleted gp140 may 239 
be different, these structural data do suggest that the CD4bs-cross-linked antigen may 240 
substantially impact exposure of the C1 epitope on the Env immunogen.   241 
Induction of CD4 binding site (CD4bs) antibodies by vaccination.  242 
Since the design of the gp140-M64U1 crosslinked immunogen involved potential modifications 243 
of gp120-CD4 interactions, we evaluated the level of CD4 binding site (CD4bs) and CD4-244 
inducible (CD4i) antibodies by measuring binding of the antibodies to gp120 structures with and 245 
without mutations that are known to interfere with recognition of CD4bs and CD4i epitopes (57).  246 
In particular, the D368R mutation abrogates binding of most CD4bs antibodies to gp120 core or 247 
gp120 (28, 57-60), Δ371 abrogates binding of VRC01-like antibodies to gp120 resurfaced 248 
stabilized core (RSC3) (57, 59), and the I420R mutation abrogates binding of gp120 core to 249 
17b-like CD4i antibodies (28, 59). With these reagents, we detected CD4bs binding antibodies 250 
(indicated by YU gp120 core WT:D368R ratios ≥ 2.5) in both vaccination groups (Fig. 3A) with 251 
comparable levels between the 2 groups (Table 2). Furthermore, VRC01-like binding antibodies 252 
(indicated by RSC3 WT:∆371 ≥ 2.5) developed in both vaccination groups at generally 253 
comparable levels (Fig. 3A, Table 2). 17b-like CD4i antibodies, defined as HXB2 8b core 254 
WT:I420R ≥2.5, were not induced (Fig. 3A).  255 
Early increase in antibody avidity with gp140-M64U1 vaccine.  256 
Maturation of the vaccine-elicited antibody response through determination of HIV-1 Env 257 
antibody avidity is an indicator of the quality of the vaccine-induced antibody responses. We 258 
measured the avidity (as dissociation rate constant (off-rate), kd, and avidity score, RU/kd) of 259 
purified serum IgG (from wk 6, wk 26, wk 38, wk 107, and wk 113) for binding to SF162 260 
gp140ΔV2 (Fig. 3B), MN gp120 (Fig. 3C), MN gp41 (Fig. 3D), and ConS gp140 (Fig. 3E). The 261 
avidity scores of serum IgG to these antigens peaked at wk26 and wk38 (Fig. 3F), and off-rates 262 
dropped to lowest levels (slowest off-rates) at the same time-points (Fig. 3B-3F). At wk 6, off-263 
rate for SF162 gp140ΔV2 was significantly slower in the gp140-M64U1 group compared to the 264 
gp140 group (median 1.7 x 10-4 versus 1.0 x 10-3 S-1 for gp140-M64U1 and gp140 groups 265 
respectively, FDR_p=0.022, Fig. 3B, Table 2). Off-rates were not statistically different, after 266 
FDR correction, for the two vaccine groups at wk 26, wk 38, and wk 113 (Fig. 3B-3F, Table 2). 267 
The longitudinal patterns of antibody off-rates and avidity score for gp41, gp120, and ConS 268 
gp140 were similar to that for SF162 gp140ΔV2, with the gp140-M64U1 group trending toward 269 
having a slower off-rate (Fig. 3C,3D, and 3E) and higher avidity score (Fig 3F) than the gp140 270 
group.   271 
Serum IgG Env binding avidity and magnitude correlate with ADCC and neutralization. 272 
We further explored correlations between binding antibody properties (binding MFI and off-273 
rates) and antiviral functions (neutralization and ADCC) of antibodies elicited in the study. 274 
Vaccinations elicited low to moderate levels of neutralizing antibodies against SF162P4, with 275 
titers ranging from <10 to 4403 at the peak neutralizing activity time point of wk 38 (post 3rd 276 
immunization) in most animals (Bogers et al, submitted). Neutralization of SHIV SF162P4 at wk 277 
38 was found to correlate significantly with wk 38 serum IgG binding to SF162 gp140∆V2 278 
(FDR_p=0.003, Spearman r=0.97; Fig. 4A and Table 3). Wk 38 neutralization of SHIV 279 
SF162P4 was also found to correlate with a faster off-rate for SF162 gp140∆V2 at wk 6 280 
(FDR_p=0.006, Spearman r=0.87; Fig. 4B) which indicated an inverse correlation with avidity; 281 
however wk 38 neutralization was not significantly correlated with contemporaneous (wk 38) off-282 
rate for SF162 gp140∆V2 (Table 3).   283 
Both vaccine groups developed strong ADCC activity measured with SF162 gp120-coated cells, 284 
which peaked at wk26 after the 2nd immunization with titers up to 19,024 (Bogers et al, 285 
submitted). ADCC titers were significantly higher for the gp140-M64U1 group compared to the 286 
gp140 group (FDR_p = 0.014) at wk 26, and trended higher at wk 113 (Table 2). Correlation 287 
analysis revealed that ADCC activity at wk 26 (post 3rd immunization) was not correlated with 288 
either contemporary (wk26) binding magnitude or avidity for SF162 gp140∆V2, but rather 289 
correlated with wk6 (post 2nd immunization) serum IgG binding (FDR_p=0.003, Spearman 290 
r=0.90; Fig. 4C) and avidity (FDR_p=0.035, Spearman r=-0.73 for off-rate; Fig. 4D and Table 3) 291 
for SF162 gp140∆V2, indicating that binding antibody responses early on may predict later 292 
antibody functions following further immunizations.     293 
Low level of serum IgA elicited.  294 
Env-specific IgA responses were evaluated in longitudinal serum samples. The overall 295 
magnitudes of HIV-1 Env serum IgA responses were much lower than serum IgG responses 296 
(Fig. 5A vs. Fig. 1A), with IgA binding positivity rates of 66.7% and 66.7% at wk 26 for SF162 297 
gp140ΔV2 for gp140 and gp140-M64U1 groups, respectively, compared to 100% and 100% for 298 
IgG binding to SF162 gp140ΔV2 at wk 26. Similar to serum IgG responses, serum IgA binding 299 
to SF162 gp140ΔV2 peaked earlier for the gp140-M64U1 group, at wk 6, compared to wk 26 for 300 
the gp140 group (Fig. 5A). However, no significant difference between the two groups in the 301 
magnitude of responses was detected for wk6 or for any time point (Fig. 5A, Table 2).  302 
Vaccine-elicited mucosal antibody responses.  303 
Nasal and rectal samples were collected from vaccinated animals at wk 38. Env-specific IgG 304 
responses were evaluated in these mucosal samples using BAMA (29, 43).Binding magnitude 305 
(MFI) was normalized to total recovered rhesus IgG concentration (µg/ml) in each mucosal 306 
sample to account for sampling variations. Total rhesus IgG ranged from <0.5-109 µg/ml 307 
(median 9.1 µg/ml) and <0.5-165 µg/ml (median 9.9 µg/ml) for nasal and rectal samples, 308 
respectively. We detected Env-specific IgG against SF162 gp140∆V2, MN gp120, and MN gp41 309 
in nasal washes from both the gp140 and gp140-M64U1 groups with comparable magnitudes 310 
(Fig. 5B, and data not shown). When compared to the mock immunized control animals, nasal 311 
samples from the gp140 group showed significantly higher levels of SF162 gp140ΔV2 specific 312 
antibodies (FDR_p=0.022, Table 2). The specific IgG binding of the rectal washes from the 313 
vaccinated animals to these Env proteins was not statistically different from that of control 314 
animals (data not shown).  We further examined the correlation between IgG responses in the 315 
serum and the mucosal compartments and found a lack of significant correlation between serum 316 
and nasal IgG responses for binding to SF162 gp140∆V2 (Fig. 5C), indicating that these are 317 




Here we report on the detailed binding specificities, avidity, kinetics and functional correlations 322 
of antibodies generated by immunization of rhesus macaques with an HIV-1 envelope protein 323 
(SF162∆V2 gp140) cross-linked with a CD4 mimetic miniprotein, M64U1 (Bogers et al, 324 
submitted). Our findings demonstrate that cross-linking of the CD4 mimetic M64U1 with gp140 325 
significantly impacts the kinetics, binding specificity, avidity and ADCC activity of the vaccine-326 
elicited antibodies compared to that of gp140 protein alone. Comparison of the binding antibody 327 
responses between the gp140 and the gp140-M64U1 groups revealed an accelerated 328 
development of anti-Env binding responses in the gp140-M64U1 group, as indicated by higher 329 
binding to gp120 and gp140 Env proteins compared to the gp140 alone group at wk 6 (post 2nd 330 
immunization) (Fig.1, Table 2). However, Env binding responses became comparable by the 331 
time antibody responses peaked (at wk 26 and wk 38, post 3rd and 4th immunization, 332 
respectively), whereas binding to a linear C1 epitope was higher for the gp140 group compared 333 
to the gp140-M64U1 group at wk 26. Antibody responses against M64U1 or CD4 were not 334 
measured in this current study. Follow-up studies could examine whether anti-immunogen 335 
responses were elicited and could have impacted gp140 antibody responses in the gp140-336 
M64U1 group following later boosts.  337 
  338 
In previous study in rabbits (42), the gp140-M64U1 complex elicited significant levels of CD4i 339 
antibodies as measured by absorption/depletion with gp120 proteins carrying the I420R 340 
mutation, which is critical for binding by 17b-like CD4i antibodies, and by neutralization of a HIV-341 
1 virus with and without the presence of soluble CD4. In the current NHP study, no significant 342 
17b-like CD4i antibody responses were detected in either the gp140 or the gp140-M64U1 group 343 
when examining the differential binding of serum to gp120 core protein with and without the 344 
I420R mutation (Fig. 3A). Another difference between the previous rabbit study and the current 345 
macaque study is the higher levels of neutralizing antibodies directed to the CD4i epitopes 346 
observed in the rabbit study following gp140-M64U1 immunization but not the current macaque 347 
study (Bogers et al., submitted). Apart from differences in study methods, species differences 348 
may play a role in the difference observed. Macaques have intrinsic expression of CD4 349 
molecules along with other surface molecules including co-receptor and DC-SIGNs (61-63) that 350 
could interact with and SIV and HIV Env, which likely affects the responses of macaques to a 351 
miniCD4-crosslinked Env.  One concern for the use of CD4 mimetic proteins in vaccine 352 
regimens is the potential effect on the development of CD4bs antibodies. Broadly neutralizing 353 
CD4bs antibodies have been shown to recognize a site of “vulnerability” on the HIV-1 Env (64). 354 
Binding antibodies directed to CD4bs are commonly induced in HIV infection (57), but 355 
unfortunately those with broadly neutralizing activity seem to develop in a smaller subset of 356 
individuals (57, 65). CD4bs antibodies were detected in the gp140 group in the rabbit study (42). 357 
In the current study, we also found comparable levels of CD4bs antibodies in both the gp140 358 
and the gp140-M64U1 groups (Fig. 3A).  359 
One surprising finding in this study is the impact of M64U1-Env crosslinking on the 360 
kinetics, specificity, and avidity of antibody responses. Both the binding magnitude and avidity of 361 
the Env-specific antibodies were significantly higher (FDR_p=0.014) for the gp140-M64U1 362 
group at wk 6 (post 2nd immunization), although the two groups either were comparable or the 363 
gp140 group trended higher than the gp140-M64U1 group at later time points (Fig. 1A-1D, and 364 
Fig. 3C, Table 2). The mechanisms for the faster development of antibody responses in the 365 
gp140-M64U1 group are not clear and warrant further investigation, including whether 366 
crosslinking of M64U1 and gp140 can affect the stability and in vivo trafficking of the Env 367 
protein, and how the crosslinking with M64U1 affects the interaction of Env with cells of both the 368 
adaptive and innate immune systems. In particular, exploring of the B cell responses in this 369 
macaque study revealed higher proportions of Env-specific B cells in peripheral blood 370 
mononuclear cells (PBMC) (Bogers et al., submitted). Bogers et al. hypothesized that 371 
crosslinking with M64U1 interferes with CD4 receptor engagement, thus improving CD4 T cell-372 
dependent immune responses.  373 
In contrast to the binding results with the Env proteins, binding to a C1 epitope, C1_104: 374 
MQEDVISLWDQSLKPCVKLTPLCV (sequence matches that of AE clade consensus), was 375 
significantly higher for the gp140 group compared to the gp140-M64U1 group at the peak 376 
immunity time point of wk 26, as shown by both linear epitope mapping microarray and by 377 
BAMA (Fig. 2A, 2B, and 2F, Table 2). Plasma IgA responses to this same epitope were 378 
positively correlated with HIV-1 risk in the human RV144 vaccine clinical trial (20). Quantification 379 
of the anti-C1.2 IgA response was not possible in this study due to the low levels of overall IgA 380 
responses. Characterization of IgA responses against this C1 epitope and its correlation with 381 
ADCC response warrant further investigation. In addition, even though conformational C1-382 
binding IgA has been indicated as potentially blocking IgG-mediated ADCC activity (66) and 383 
monoclonal IgG antibodies targeting conformational C1 epitopes can synergize with V2 384 
antibodies for increased ADCC and neutralizing activities (50), the role of C1-linear binding IgG 385 
in vaccine protection is not yet understood. 386 
Another interesting finding in the study was the significantly higher ADCC activity in the 387 
sera of animals in the gp140-M64U1 group at wk26 (Bogers et al., submitted, and Table 2). 388 
ADCC activity was not measured for wk 6 serum, the only time point where Env-binding 389 
magnitude was higher in the gp140-M64U1 group compared to the gp140 group. ADCC activity 390 
at wk 26 significantly correlated with wk6 Env binding magnitude and off-rate (Fig. 4C and D), 391 
but not with wk26 (contemporary) binding magnitude or off-rate (Table 3). The brisk and avid 392 
antibody response may be a biomarker for another underlying (and unmeasured) mechanism 393 
that led to enhanced ADCC function or alternatively, the early antibody response directly 394 
impacted the immune mechanisms resulting in higher ADCC function.  Interestingly, ADCC 395 
activity was also found to correlate with proportions of Env-specific B cells in peripheral blood in 396 
the same study (Bogers et al., submitted). Wk38 serum neutralizing activity, on the other hand, 397 
correlated with contemporary IgG binding magnitude (Fig. 4A) but not the contemporary IgG 398 
Env avidity; it also correlated with a faster off-rate (indicating lower avidity) at the earlier time 399 
point of wk6 (Fig. 4B) The discordant correlations of ADCC and neutralizing activities with 400 
binding and avidity are in agreement with the observations from Guan et al. (67), suggesting 401 
that different Env specificities are involved in ADCC and neutralizing anti-viral functions.  402 
  403 
Env-specific antibodies were detected in nasal samples in both the gp140 and gp140-404 
M64U1 groups, with no difference in IgG levels between groups. The level of Env-specific IgG in 405 
the nasal compartment did not correlate with serum IgG. This could be explained by selective 406 
transportation of serum IgG into mucosal compartments, variation in transportation efficiency 407 
among animals, or local production of IgG at the mucosal compartments. The Env gp140 used 408 
in this vaccine study does not contain V2. This was based on an earlier finding of higher titers of 409 
cross-reactive neutralizing antibodies in rhesus macaques immunized with SF162 V2-loop 410 
deleted gp140 compared to those immunized with SF162 gp140 (33, 68). In light of the RV144 411 
immune correlation found between plasma anti-V2 IgG and decreased risk of infection (20), 412 
further studies to improve upon this vaccine platform could include the addition of the V2 region 413 
in the vaccine immunogen to enable induction of V2-specific responses. 414 
 415 
In summary, data from this study indicate that immunizing with an Env protein cross-416 
linked to the CD4 mimetic miniprotein (M64U1) induced accelerated Env binding magnitude and 417 
avidity (as early as 2 weeks post 2nd immunization). In addition, crosslinking of gp140 with 418 
M64U1 modulated particular epitope specificities of antibody responses, such as inducing 419 
higher C1_104.AE responses in the gp140 group, likely due to alterations in the envelope 420 
structure that modulate exposure of this region upon CD4 binding. Lastly, ADCC activity at peak 421 
immunity time points (which were higher for the gp140-M64U1 group compared to the gp140 422 
group) correlated with the magnitude and avidity of Env binding responses at an earlier time 423 
point before the ADCC and binding antibody responses reached peak levels. Taken together, 424 
these data indicate that structural modification of HIV-1 Envelope immunogens by mimicking the 425 
CD4 bound state can modulate epitope exposure in a way that substantially impacts the 426 
specificity and function of the elicited antibody responses. 427 
 428 
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Figure Legends  444 
Figure 1. Longitudinal binding antibody responses for SF162 gp140∆V2 (vaccine strain) (A), 445 
ConS gp140 (B), MN gp120 (C), and MN gp41 (D). Shown are MFI binding values within the 446 
linear range of the assay for each antigen (1:400 for SF162 gp140∆V2 and MN gp41; 1:80 for 447 
ConS gp140 and MN gp120). The gp140 group is shown in blue, and the gp140-M64U1 group 448 
in red. For improved data visualization of data points with similar magnitude, the x-axis is plotted 449 
categorically with staggered symbols so each data point is visible. One animal in the gp140-450 
M64U1 died before wk107, and serum samples were not available for another 3 animals in the 451 
gp140-M64U1 group at wk107, therefore leaving 2 data points for wk107 and 5 data points for 452 
the gp140-M64U1 group. Green arrows below x-axis indicate time of vaccinations. FDR_p: 453 
Wilcoxon rank sum exact test p value controlled for false discovery rate (FDR) with the 454 
Benjamini-Hochberg method. * indicate FDR_p<0.05.  455 
 456 
Figure 2. Linear epitope specificity of serum IgG by epitope mapping (A-E) and BAMA (F). Wk 457 
26 mean binding intensity values of serum IgG for the gp140 only (B, D) and gp140-M64U1 458 
(C,E) groups are shown for overlapping peptides of 7 consensus gp120 (B,C) and gp41 ( D, E) 459 
sequences, respectively. Different colors represent different clade/circular recombinant forms 460 
(CRFs). Epitope regions identified in the study are indicated with text over horizontal bars in 461 
plots. (A.) Magnitude of binding to each epitope, calculated as the highest binding to a single 462 
peptide within each epitope region, wherein percentage numbers listed under each epitope are 463 
the response rates to the epitope by the 2 groups (gp140 vs. gp140-M64U1). The peptide 464 
ranges for the epitopes are: C1.1: #16-21; C1.2: #32-39; C2: #65-68; V3: #97-104; C4: #133-465 
139; V5-C5: #147-151; C5.1: #152-159; C5.2: #161-163; gp41-ID: #187-194. Sequences for all 466 
peptides have been previously published (47). Longitudinal binding to C1_104.AE peptide 467 
(corresponds to C1.2 epitope in epitope mapping) was measured by BAMA and is shown in 468 
panel F. Green arrows indicate time of immunizations. (G.) Structural modeling of the 469 
conformational change of the C1 epitope upon CD4 binding. The C1_104 epitope bends ~90 470 
degrees from the unliganded gp120 conformation (gp120 monomer from SOSIP Env trimer; 471 
PDB 4TVP; beige) to the CD4 liganded gp120 conformation (PDB 4RQS; light blue). Binding of 472 
CD4 (PDB 4QRS; green) results in a >30Å displacement of the C-terminal residue (stick 473 
representation) between the C1_104 epitope in the unliganded gp120 (red) versus the CD4 474 
bound C1_104 epitope (magenta).   475 
 476 
 477 
Figure 3. CD4bs and CD4i specificity (A) and off-rate measurements for SF162 gp140∆V2 (B), 478 
MN gp120, (C), MN gp41 (D), and ConS gp140 (E) in the 2 vaccine groups, and the group 479 
mean off-rates and avidity score values measured by SPR are shown (F). The cutoff for the 480 
CD4bs and CD4i differential binding assay (A) is 2.5-fold. For the CD4bs/CD4i differential 481 
binding assay, b12 (CD4bs mAb) was used as positive control for YU gp120 Core WT:D368R 482 
differential binding and RSC3 WT:∆371 differential binding (57), and 17b (CD4i mAb) was used 483 
as positive control for HXB2 8b core WT:I420R differential binding (28, 57). Serum samples 484 
were tested at 1:400. Control mAbs b12 and 17b were tested as 25 and 50 µg/ml, respectively. 485 
All baseline serum samples were negative for binding to both the WTs and mutants in this test 486 
panel. Green arrows indicate times of immunizations. FDR_p: Wilcoxon rank sum exact test p 487 
value controlled for false discovery rate (FDR) with the Benjamini-Hochberg method. * indicate 488 
FDR_p<0.05. Between-group comparison test results are shown in Table 2.    489 
 490 
Figure 4. Correlation of neutralization (A,B) and ADCC (C,D) activities with serum IgG binding 491 
magnitudes (A&C) and serum IgG avidity (B&D). Spearman correlation analysis was performed 492 
using SAS, and p values are FDR corrected across all between-group comparison tests (Table 493 
2) and this correlation test (Table 3). ** FDR_p<0.01; * FDR_p<0.05.  494 
 495 
Figure 5. Longitudinal binding of serum IgA to SF162 gp140∆V2 (A), wk 38 nasal IgG binding to 496 
SF162 gp140∆V2 (B), and correlation between serum and nasal IgG binding to SF162 497 
gp140∆V2 at wk 38 (C). MFI binding values shown for IgA binding are from 1:80 serum dilution. 498 
Binding specificities for nasal samples were normalized by total IgG concentration in each 499 
sample. Green arrows indicate time of immunizations *FDR_p<0.05 (Wilcoxon Rank Sum Exact 500 
Test, FDR correction with Benjamini & Hochberg method). 501 
 502 
Table 1. Immunization Schedule 503 
Group Immunogen Dose (mg) Adjuvant Route Time (Weeks) # of animals 
1 SF162 gp140∆V2 100 MF59 IM 0, 4, 24, 36, 107 N=6 
2 M64U1 50 MF59 IM 0, 4, 24, 36, 107 N=6 
3 M64U1-SF162 gp140∆V2 100 MF59 IM 0, 4, 24, 36, 107 N=6 
4 --- --- MF59 IM 0, 4, 24, 36, 107 N=6 
 504 
Table 2. Between group comparisons with False Discovery Rate [FDR] controlled p values.  505 
  Measurement Raw_p FDR_p 
Serum IgG Binding BAMA (MFI), gp140 vs gp140-M64U1 
SF162 gp140∆V2 /wk6 0.002 0.014* 
SF162 gp140∆V2 /wk26 0.485 0.614 
SF162 gp140∆V2 /wk38 0.026 0.071 
SF162 gp140∆V2 /wk113 0.017 0.052 
ConS gp140 /wk6 0.002 0.014* 
ConS gp140 /wk26 0.818 0.897 
ConS gp140 /wk38 0.015 0.052 
ConS gp140 /wk113 0.017 0.052 
MN gp120 /wk6 0.002 0.014* 
MN gp120 /wk26 0.818 0.897 
MN gp120 /wk38 0.093 0.189 
MN gp120 /wk113 0.030 0.075 
MN gp41 /wk6 0.002 0.014* 
MN gp41 /wk26 0.180 0.277 
MN gp41 /wk38 0.180 0.277 
MN gp41 /wk113 0.126 0.231 
C1_104.AE /wk6 0.180 0.277 
C1_104.AE /wk26 0.002 0.014* 
C1_104.AE /wk38 0.015 0.052 
  C1_104.AE /wk113 0.082 0.180 
Serum IgG Avidity SPR (off-rate, kd), gp140 vs gp140-M64U1 
SF162 gp140∆V2 /wk6 0.004 0.022* 
SF162 gp140∆V2 /wk26 0.699 0.813 
SF162 gp140∆V2 /wk38 0.041 0.098 
  SF162 gp140∆V2 /wk113 0.017 0.052 
$Serum IgG ADCC (Titer), gp140 vs gp140-M64U1 
SF162 gp140∆V2 /wk26 0.002 0.014* 
  SF162 gp140∆V2 /wk113 0.126 0.231 
$Serum Neutralization (ID50), gp140 vs gp140-M64U1 
SHIV-SF162P4 /wk38 0.026 0.071 
SHIV-SF162P4 /wk42 0.506 0.628 
  SHIV-SF162P4 /wk113 0.126 0.231 
Serum Linear Epitope Mapping (Signal Intensity), gp140 vs gp140-M64U1 
C1.1  /wk26 0.028 0.073 
C1.2 /wk26 0.009 0.038* 
C2  /wk26 0.318 0.422 
V3 /wk26 0.937 0.948 
C4 /wk26 0.387 0.502 
V5-C5 /wk26 0.242 0.343 
C5.1 /wk26 0.180 0.277 
C5.2 /wk26 0.937 0.948 
gp41-ID  /wk26 0.240 0.343 
  gp160 total /wk26 0.093 0.189 
CD4bs panel BAMA (WT:mutant ratio), gp140 vs gp140-M64U1 
RSC3 WT:∆371 /wk26 0.536 0.650 
  YU gp120 core WT:D368R /wk26 0.043 0.099 
Serum IgA Binding BAMA (MFI), gp140 vs gp140-M64U1 
SF162 gp140∆V2 /wk6 0.180 0.277 
SF162 gp140∆V2 /wk26 0.937 0.948 
SF162 gp140∆V2 /wk38 0.310 0.420 
  SF162 gp140∆V2 /wk113 0.247 0.343 
Nasal IgG Binding BAMA (Specific Activity), gp140 vs gp140-M64U1 
  SF162 gp140∆V2 /wk38 0.132 0.235 
Nasal IgG Binding BAMA (Specific Activity), gp140 vs mock control 
  SF162 gp140∆V2 /wk38 0.004 0.022* 
Nasal IgG Binding BAMA (Specific Activity), gp140-M64U1 vs M64U1 control 
  SF162 gp140∆V2 /wk38 0.015 0.052 
 506 
$Quantification of neutralization and ADCC responses are reported by Bogers et al. (submitted).   507 
Raw_p: Wilcoxon Rank Sum Exact Test [p-value], not corrected for multiple comparisons. 508 
FDR_p: Controlling the False Discovery Rate, FDR_p values are calculated according to 509 
Benjamini & Hochberg (1995). FDR was performed across Wilcoxon Rank Sum tests in Table 2 510 
and Spearman correlation test in Table 3 (57 tests total).  511 
P values in bold font are <0.05.  512 
* Significant difference between groups (FDR_p <0.05).    513 
 514 
Table 3. Spearman correlation test with False Discovery Rate (FDR) control for correlation 515 
between antibody functions (ADCC or neutralization) and binding antibody responses (avidity or 516 
IgG binding), and between nasal and serum IgG responses.  517 
Parameter 1 Parameter 2 Raw_p FDR_p Spearman r
wk26 ADCC (linear titer) wk6 off-rate (kd) 0.0074 0.035* -0.73
wk26 ADCC (linear titer) wk26 off-rate (kd) 0.95 0.948 -0.021
wk26 ADCC (linear titer) wk6 IgG binding (BAMA MFI) < 0.0001 0.003* 0.9
wk26 ADCC (linear titer) wk26 IgG binding (BAMA MFI) 0.91 0.948 0.035
wk38 neutralization (ID50 titer) wk6 off-rate (kd) 0.0003 0.006* 0.87
wk38 neutralization (ID50 titer) wk38 off-rate (kd) 0.75 0.850 -0.1
wk38 neutralization (ID50 titer) wk6 IgG binding (BAMA MFI) 0.2 0.298 -0.4
wk38 neutralization (ID50 titer) wk38 IgG binding (BAMA MFI) < 0.0001 0.003* 0.97
Nasal IgG (SA) Serum IgG binding (MFI) 0.56 0.661 0.19
Raw_p: Spearman's rank correlation test [p-value], not corrected for multiple comparisons. 518 
FDR_p: Controlling the False Discovery Rate, FDR_p values are calculated according to 519 
Benjamini & Hochberg (1995). FDR was performed across Wilcoxon Rank Sum tests in Table 2 520 
and Spearman correlation test in Table 3 (57 tests total). 521 
Bolded p values are <0.05. 522 
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